Keyword: Randall Stanicky
Allergan's shares have significantly fallen from their highs in 2015, but now the company is ready to make a big move, one analyst writes.
Think $1.9 billion in back taxes looks bad? Perrigo was knocked Monday for $873 million in unpaid royalties as part of its sale of MS drug Tysabri.
A major Allergan pipeline candidate may have failed a pivotal trial, but investors cheered the news. The reason? They’re anticipating a company split.
When Mylan said last month that it would consider a sale, analysts were skeptical the company could find an interested buyer.
It was nearly two years ago that activist investors began urging Perrigo to hive off its specialty pharma unit. Now, it’s finally happening.
Billionaire David Tepper has permission to make an activist run at Allergan. Will he use it—and if so, how?
Just five months after Allergan’s CEO said the company wouldn’t break up, it’s reportedly weighing options for its women’s health unit.
